KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company's products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: KMPH
- Previous Close: $3.85
- 50 Day Moving Average: $3.55
- 200 Day Moving Average: $3.98
- 52-Week Range: $2.90 - $19.75
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.45
- P/E Growth: 0.00
- Market Cap: $57.85M
- Outstanding Shares: 14,646,000
- Beta: -1.46
- Return on Assets: -17.21%
Companies Related to KemPharm:
- Debt-to-Equity Ratio: -9.26%
- Current Ratio: 11.45%
- Quick Ratio: 11.45%
What is KemPharm's stock symbol?
KemPharm trades on the NASDAQ under the ticker symbol "KMPH."
Where is KemPharm's stock going? Where will KemPharm's stock price be in 2017?
3 brokerages have issued 1-year price targets for KemPharm's stock. Their predictions range from $9.00 to $14.00. On average, they expect KemPharm's share price to reach $12.00 in the next twelve months.
When will KemPharm announce their earnings?
KemPharm is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.
Who owns KemPharm stock?
KemPharm's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include DSC Advisors L.P. (9.96%), Deerfield Management Co. (7.40%), Alyeska Investment Group L.P. (6.82%), Federated Investors Inc. PA (1.37%) and Menta Capital LLC (0.32%). Company insiders that own KemPharm stock include Daniel L Cohen and Travis C Mickle.
Who bought KemPharm stock? Who is buying KemPharm stock?
KemPharm's stock was acquired by a variety of institutional investors in the last quarter, including DSC Advisors L.P. and Alyeska Investment Group L.P.. Company insiders that have bought KemPharm stock in the last two years include Daniel L Cohen and Travis C Mickle.
How do I buy KemPharm stock?
Shares of KemPharm can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of KemPharm stock cost?
One share of KemPharm stock can currently be purchased for approximately $3.95.